Feasibility and benefits of scaling up antiretroviral treatment provision with the 2010 WHO antiretroviral therapy guidelines in rural Lesotho

International Health

Volumn 4, Issue 3, 2012, Pages 170-175

  Bygrave, Helen ^a   Saranchuk, Peter ^a   Makakole, Lipontso ^b   Ford, Nathan ^a,c  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b Scott Hospital   (Lesotho)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Antiretroviral therapy; Early initiation; Resource limited setitngs; Tenofovir; WHO guidelines

Indexed keywords

CD4 ANTIGEN; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; DECENTRALIZATION; DRUG SUBSTITUTION; FEASIBILITY STUDY; HEALTH CARE PERSONNEL; HEALTH INSURANCE; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LESOTHO; MONITORING; MORTALITY; PATIENT CARE; PATIENT COMPLIANCE; PHARMACY; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RURAL AREA; SCALE UP; TEACHER; TOXICITY; TRAINING; WORLD HEALTH ORGANIZATION;

EID: 84865571828     PISSN: 18763413     EISSN: 18763405     Source Type: Journal    
DOI: 10.1016/j.inhe.2012.06.002     Document Type: Article

References (34)

1. WHO. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Geneva: World Health Organization; 2009.
2. Hirnshall G. The new WHO recommendations for HIV treatment. Geneva: World Health Organization; 2010.
3. MSF. MSF medical activity report 2010. Brussels: Médecins Sans Frontières; 2011.
4. Department of Health. Clinical guidelines for the management of HIV & AIDS in adults and adolescents. National Department of Health, South Africa 2010.
5. IRIN News Service. ZIMBABWE: New treatment guidelines rolled out - a year later. Nairobi: Integrated Regional Information Networks; ©2012. http://www.plusnews.org/report.aspx?reportid=92452 [accessed 21 June 2012].
6. Schouten E.J., Jahn A., Midiani D., et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet 2011, 378:282-284.
7. Cohen R., Lynch S., Bygrave H., et al. Antiretroviral treatment outcomes from a nurse-driven, community supported HIV/AIDS treatment programme in rural Lesotho: observational cohort assessment at two years. J Int AIDS Soc 2009, 12:1-8.
8. Ministry of Health and Social Welfare. Lesotho national guidelines for antiretroviral therapy in adults and adolescents. Maseru: Ministry of Health and Social Welfare, 2007.
9. MSF. Management of HIV related conditions and antiretroviral therapy in adults and children; HIV guide for primary health care in Lesotho. Morija: Médecins Sans Frontières; 2008.
10. Bygrave H., Kranzer K., Hilderbrand K., et al. Renal safety of a tenofovir-containing first-line regimen: experience from an antiretroviral cohort in rural Lesotho. Plos One 2011, 6:1-5.
11. Llibre JM, Arribas JR, Domingo P, et al. Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. AIDS 2011 [Epub ahead of print].
12. Severe P., Jean Juste M.A., Ambroise A., et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010, 363:257-265.
13. Mills E, Bakanda C, Birungi J, et al. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: Evidence from a large cohort in Uganda. AIDS 2011 [Epub ahead of print].
14. Ford N., Kranzer K., Hilderbrand K., et al. Early initiation of antiretroviral therapy and associated reduction in mortality and morbidity and defaulting in a nurse-managed, community cohort in Lesotho. AIDS 2010, 24:2645-2650.
15. Bygrave H, Ford N, van Cutsem G, et al. Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years. J Acquir Immune Defic Syndr 2010 [Epub ahead of print].
16. Calmy A., Klement E., Teck R., et al. Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling up. AIDS 2004, 18:2353-2360.
17. The Antiretroviral Pregnancy Registry. Interim report. Wilmington: Antiretroviral Pregnancy Registry. 2011 [accessed 1 January 2012]. http://www.apregistry.com/forms/interim_report.pdf.
18. Ford N., Mofenson L., Kranzer K., et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS 2010, 24:1461-1470.
19. Baylor M.S., Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004, 35:538-539.
20. Reid A, Stohr W, Walker S, et al. on behalf of the DART trial. Glomerular dysfunction and associated risk factors following initiation of ART in adults with HIV infection in Africa. Fifth IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2005; Cape Town. Abstract ThAB0105.
21. WHO Regional Office for Africa. HIV and AIDS Laboratory Capacity. Where are we? Overview of laboratory capacity in Africa 2005-2007. Brazzaville: World Health Organization. http://www.afro.who.int/en/clusters-a-programmes/dpc/acquired-immune-deficiency-syndrome/features/2736-hiv-and-aids-laboratory-capacity.html [accessed 21 June 2012].
22. Bolton C, Topp S, Rossi V, Ojikutu B. From paper to practice: implementing the World Health Organization's 2010 antiretroviral therapy recommendations for adults and adolescents in Zambia. Case Study Series. Arlington, VA: USAID's AIDS Support and Technical Assistance Resources, AIDSTAR-One, Task Order 1;2011.
23. Kenyon C., Wearne N., Burton R., Meintjes G. The risk of concurrent treatment with tenofovir and aminoglycosides in patients with HIV-associated tuberculosis. South Afr J HIV Med 2011, 12:43-45.
24. Jouquet G, Bygrave H, Kranzer K, et al. Cost and cost-effectiveness of switching from stavudine or zidovudine to a TDF-based first-line regimen in a resource limited setting in rural Lesotho. J Acquir Immune Defic Syndr 2011 [Epub ahead of print].
25. Ford N., Calmy A., Hurst S. When to start antiretroviral therapy in resource-limited settings: a human rights analysis. BMC Int Health Hum Rights 2010, 10:6.
26. Grinsztejn B, Ribaudo H, Cohen MS, et al. Effects of early versus delayed initiation of antiretroviral therapy (ART) on HIV clinical outcomes: results from the HPTN 052 randomized clinical trial. Sixth IAS Conference on HIV Pathogenesis, Treatment and Prevention. 2011; Rome. Abstract MOAX0105.
27. Jonsson Funk M, Fusco JS, Coleet SR, et al. HAART initiation and clinical outcomes: insights from the CASCADE cohort of HIV-1 seroconverters on 'When to Start'. Eighteenth International AIDS Conference. 2010; Vienna. Abstract THLBB201.
28. The HIV-CAUSAL Collaboration. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining conditions in HIV-infected persons in developed countries. Ann Int Med 2011;154: 509-15.
29. Cohen M.S., Chen Y.Q., McCauley M., et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011, 365:493-505.
30. University of Minnesota - Clinical and Translational Science Institute. Strategic timing of antiretroviral treatment (START). ClinicalTrials.gov Study NCT00867048. http://clinicaltrials.gov/ct2/show/NCT00867048?term=start&rank=1 [accessed 21 June 2012].
31. French National Agency for Research on AIDS and Viral Hepatitis. Early antiretroviral treatment and/or early isoniazid prophylaxis against tuberculosis in HIV-infected adults (ANRS 12136 TEMPRANO). ClinicalTrials.gov Study NCT00495651. http://clinicaltrials.gov/ct2/show/NCT00495651?term=temprano&rank=1 [accessed 21 June 2012].
32. Konde-Lule J., Makumbi F., Pakker N., Muyinda A., Mubiru M., Cobelens F.G. Effect of changing antiretroviral treatment eligibility criteria on patient load in Kampala, Uganda. AIDS Care 2011, 23:35-41.
33. EACS European AIDS Clinical Society. Guidelines: Version 6 - October 2011. Paris: European AIDS Clinical Society. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines-v6.0-English.pdf [accessed 21 June 2012].
34. Walensky R.P., Wood R., Ciaranello A.L., et al. Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. PLoS Med 2010, 7:e1000382.